Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2023 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
January 05, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina...
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
December 16, 2022 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company has...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 22, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
November 18, 2022 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and...
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 07, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
Plans to submit 24-month Phase 3 data to the FDA for intravitreal pegcetacoplan for geographic atrophy (GA); expected PDUFA target action date in February 2023EU marketing authorization application...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
November 03, 2022 16:01 ET
|
Apellis Pharmaceuticals, Inc.
Inclusion of the 24-month data has the potential to strengthen the product profile at launch, with minimal impact to launch timing Submission will be a Major Amendment to the New Drug Application...